Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

396 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill.
Bromfield GP, Meng A, Warde P, Bristow RG. Bromfield GP, et al. Prostate Cancer Prostatic Dis. 2003;6(1):73-85. doi: 10.1038/sj.pcan.4500628. Prostate Cancer Prostatic Dis. 2003. PMID: 12664070
For each cell culture, we also determined total apoptotic and overall radiation cell kill using a short-term nuclear morphologic assay and a long-term clonogenic survival assay, respectively. ...Using a flow cytometric proliferation assay with the PrSC (strom …
For each cell culture, we also determined total apoptotic and overall radiation cell kill using a short-term nuclear morphologic assa …
Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.
Lalonde E, Alkallas R, Chua MLK, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, Fradet Y, Têtu B, Lindberg J, Egevad L, Grönberg H, Ross-Adams H, Lamb AD, Halim S, Dunning MJ, Neal DE, Pintilie M, van der Kwast T, Bristow RG, Boutros PC. Lalonde E, et al. Eur Urol. 2017 Jul;72(1):22-31. doi: 10.1016/j.eururo.2016.10.013. Epub 2016 Nov 1. Eur Urol. 2017. PMID: 27815082
Finally, the 31-locus genomic classifier was implemented using a NanoString assay. The study is limited to retrospective cohorts. ...We validated a test based on prostate tumor DNA that improves estimations of relapse risk, and that can help guide treatment planning …
Finally, the 31-locus genomic classifier was implemented using a NanoString assay. The study is limited to retrospective cohorts. ... …
Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells.
Kumareswaran R, Chaudary N, Jaluba K, Meng A, Sykes J, Borhan A, Hill RP, Bristow RG. Kumareswaran R, et al. Radiother Oncol. 2015 Sep;116(3):388-91. doi: 10.1016/j.radonc.2015.03.027. Epub 2015 Apr 2. Radiother Oncol. 2015. PMID: 25842967
Spatial genomic heterogeneity within localized, multifocal prostate cancer.
Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, Zia A, Fox NS, Livingstone J, Shiah YJ, Wang J, Beck TA, Have CL, Chong T, Sam M, Johns J, Timms L, Buchner N, Wong A, Watson JD, Simmons TT, P'ng C, Zafarana G, Nguyen F, Luo X, Chu KC, Prokopec SD, Sykes J, Dal Pra A, Berlin A, Brown A, Chan-Seng-Yue MA, Yousif F, Denroche RE, Chong LC, Chen GM, Jung E, Fung C, Starmans MH, Chen H, Govind SK, Hawley J, D'Costa A, Pintilie M, Waggott D, Hach F, Lambin P, Muthuswamy LB, Cooper C, Eeles R, Neal D, Tetu B, Sahinalp C, Stein LD, Fleshner N, Shah SP, Collins CC, Hudson TJ, McPherson JD, van der Kwast T, Bristow RG. Boutros PC, et al. Nat Genet. 2015 Jul;47(7):736-45. doi: 10.1038/ng.3315. Epub 2015 May 25. Nat Genet. 2015. PMID: 26005866
Herein we provide a detailed molecular analysis of the spatial heterogeneity of clinically localized, multifocal prostate cancer to delineate new oncogenes or tumor suppressors. ...We identified and validated a new recurrent amplification of MYCL, which is associate …
Herein we provide a detailed molecular analysis of the spatial heterogeneity of clinically localized, multifocal prostate cancer to d …
A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, Meng A, Zhang J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Reuter VE, Fleshner N, Fraser M, Boutros PC, van der Kwast TH, Bristow RG. Chua MLK, et al. Eur Urol. 2017 Nov;72(5):665-674. doi: 10.1016/j.eururo.2017.04.034. Epub 2017 May 13. Eur Urol. 2017. PMID: 28511883 Clinical Trial.
CONCLUSIONS: The poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia. ...PATIENT SUMMARY: A constellation of unfavorable molecular characteristics co-occur with intraductal …
CONCLUSIONS: The poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SC …
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG. Dal Pra A, et al. Clin Cancer Res. 2013 Sep 15;19(18):5202-9. doi: 10.1158/1078-0432.CCR-13-1049. Epub 2013 Aug 5. Clin Cancer Res. 2013. PMID: 23918607
BACKGROUND: Preclinical data suggest that TMPRSS2-ERG gene fusions, present in about 50% of prostate cancers, may be a surrogate for DNA repair status and therefore a biomarker for DNA-damaging agents. ...TMPRSS2-ERG is therefore unlikely to be a predictive f …
BACKGROUND: Preclinical data suggest that TMPRSS2-ERG gene fusions, present in about 50% of prostate cancers, may be a surrogate for …
Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.
Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, Lam WL, Squire JA, Yoshimoto M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Milosevic M, Pintilie M, van der Kwast T, Bristow RG. Zafarana G, et al. Cancer. 2012 Aug 15;118(16):4053-62. doi: 10.1002/cncr.26729. Epub 2012 Jan 26. Cancer. 2012. PMID: 22281794
Previous reports using array comparative genomic hybridization (aCGH) in radical prostatectomy cohorts suggested a combination of allelic loss of the PTEN gene on 10q and allelic gain of the c-MYC gene on 8q were associated with metastatic disease. ...
Previous reports using array comparative genomic hybridization (aCGH) in radical prostatectomy cohorts suggested a combination of all …
Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer.
Locke JA, Zafarana G, Malloff CA, Lam WL, Sykes J, Pintilie M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Guns ET, van der Kwast T, Milosevic M, Bristow RG. Locke JA, et al. Prostate. 2012 Sep 1;72(12):1295-305. doi: 10.1002/pros.22478. Epub 2011 Dec 27. Prostate. 2012. PMID: 22213075 Clinical Trial.
METHODS: aCGH analysis of tumor DNA prospectively derived from frozen needle biopsies of 126 men with intermediate-risk disease who underwent image-guided radiotherapy (IGRT) to a mean dose of 76.4 Gy was conducted. ...The results were validated in a surgical cohort …
METHODS: aCGH analysis of tumor DNA prospectively derived from frozen needle biopsies of 126 men with intermediate-risk disease who underwen …
NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.
Locke JA, Zafarana G, Ishkanian AS, Milosevic M, Thoms J, Have CL, Malloff CA, Lam WL, Squire JA, Pintilie M, Sykes J, Ramnarine VR, Meng A, Ahmed O, Jurisica I, van der Kwast T, Bristow RG. Locke JA, et al. Clin Cancer Res. 2012 Jan 1;18(1):308-16. doi: 10.1158/1078-0432.CCR-11-2147. Epub 2011 Nov 2. Clin Cancer Res. 2012. PMID: 22048240
We tested the role of the NKX3.1 gene as a determinant of treatment outcome given its reported roles in tumor initiating cell (TIC) renewal, the DNA damage response, and cooperation with c-MYC during prostate cancer progression. ...A similar association was observed …
We tested the role of the NKX3.1 gene as a determinant of treatment outcome given its reported roles in tumor initiating cell (TIC) r …
High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer.
Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, van der Kwast T, Milosevic M, Yoshimoto M, Squire JA, Lam WL, Bristow RG. Ishkanian AS, et al. Prostate. 2009 Jul 1;69(10):1091-100. doi: 10.1002/pros.20959. Prostate. 2009. PMID: 19350549
We used a global high-resolution array comparative genomic hybridization (CGH) assay to characterize copy number alterations (CNAs) in intermediate risk prostate cancer. ...These unexpected findings suggest that the intermediate-risk category is a crucial cohort war …
We used a global high-resolution array comparative genomic hybridization (CGH) assay to characterize copy number alterations (CNAs) i …
396 results
Jump to page
Feedback